Global Net Revenue of $78.0 Million for the Third Quarter of 2026, an Increase of 13% Over the Prior Year, Supported by Double-Digit Growth in Global Toxin Revenue and Expanding Contribution from the Hyaluronic Acid
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ:EOLS). Such investors are advised to
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will participate in two upcoming investor
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ:EOLS). Such investors are advised to
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2026 financial results on Wednesday,
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ:EOLS). Such investors are advised to
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ:EOLS). Such investors are advised to contact
Potential first-in-class injectable aesthetic procedure for hair restorationEarly-stage partnership advances Evolus’ business development strategy through a disciplined, capital-efficient approach to innovationEvolus,
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or "the
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ:EOLS). Such investors are advised to contact
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ:EOLS). Such investors are advised to
The first initiative will support Look Good Feel Better® during Breast Cancer Awareness Month
Evolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of
NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size
David Gill appointed Chair of the Telix Board, effective immediately.Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair.Dr. Mark Nelson will continue to serve on
Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets
GAAP Operating Loss of $4.5
